Wasan K M, Grossie V B
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Experientia. 1995 Mar 15;51(3):230-4. doi: 10.1007/BF01931103.
We compared the effects of 0.45% normal saline (NS), 5% Intralipid (IL), and 16.7% glucose (Glu) infusions on total serum triglycerides and cholesterol, serum high-(HDL-c) and low-density lipoprotein cholesterol (LDL-c), and activity of serum lecithin:cholesterol acyltransferase (LCAT), and serum lipoprotein lipase (LPL) in rats implanted with a fibrosarcoma. In tumor-bearing rats given NS, a two-fold increase in total serum cholesterol, a four-fold increase in LDL-c, and a five-fold decrease in the HDL-c/LDL-c ratio were observed compared to tumor-free rats. In tumor-bearing rats administered IL, a two-fold increase in total serum triglyceride and cholesterol, a three-fold increase in HDL-c and HDL-c/LDL-c ratio, and a two-fold increase in LPL activity were observed compared to tumor-bearing rats administered NS. In tumor-bearing rats administered Glu, a two-fold decrease in total serum cholesterol, a two-fold decrease in HDL-c, and a three-fold decrease in LDL-c were observed compared to tumor-bearing rats administered NS. Tumor weights and LCAT activity did not differ significantly between treatment groups. Previous results have demonstrated that lipophilic compounds that interact with plasma lipoproteins have altered pharmacological effects when administered with IL. Therefore, this study suggests that IL infusions alter the HDL-c/LDL-c ratio and could affect the pharmacological behavior of anticancer compounds that predominantly distribute into the LDL fraction upon entrance into the bloodstream.
我们比较了0.45%生理盐水(NS)、5%英脱利匹特(IL)和16.7%葡萄糖(Glu)输注对植入纤维肉瘤的大鼠血清总甘油三酯和胆固醇、血清高密度脂蛋白胆固醇(HDL-c)和低密度脂蛋白胆固醇(LDL-c)以及血清卵磷脂胆固醇酰基转移酶(LCAT)和血清脂蛋白脂肪酶(LPL)活性的影响。在给予NS的荷瘤大鼠中,与无瘤大鼠相比,观察到血清总胆固醇增加两倍,LDL-c增加四倍,HDL-c/LDL-c比值降低五倍。在给予IL的荷瘤大鼠中,与给予NS的荷瘤大鼠相比,观察到血清总甘油三酯和胆固醇增加两倍,HDL-c和HDL-c/LDL-c比值增加三倍,LPL活性增加两倍。在给予Glu的荷瘤大鼠中,与给予NS的荷瘤大鼠相比,观察到血清总胆固醇降低两倍,HDL-c降低两倍,LDL-c降低三倍。各治疗组之间的肿瘤重量和LCAT活性无显著差异。先前的结果表明,与血浆脂蛋白相互作用的亲脂性化合物与IL一起给药时具有改变的药理作用。因此,本研究表明,IL输注会改变HDL-c/LDL-c比值,并可能影响进入血液后主要分布在LDL部分的抗癌化合物的药理行为。